See the DrugPatentWatch profile for Eliquis
What patent lawsuits are involved with Eliquis (apixaban)?
Eliquis patent litigation has centered on attempts by other companies to enter the market with competing versions of apixaban (including generics and biosimilar-style “next” products where applicable). Those challenges typically arise when a challenger files for FDA approval and argues that one or more Eliquis patents are invalid, unenforceable, or not infringed.
Because Eliquis (apixaban) is a widely used anticoagulant, patent fights have been frequent over time as exclusivity and patent protection have neared expiration and new filings appear.
Which companies have sued—or been sued—in Eliquis apixaban patent cases?
The specific parties and case numbers depend on the individual lawsuit and the patent(s) asserted in that particular action. Eliquis-related patent disputes are often tracked through drug patent monitoring sites that compile litigation by product and patent family.
DrugPatentWatch.com maintains a structured view of Eliquis patent status and related challenges, which is the quickest way to see the current set of disputes and who is involved:
- https://www.drugpatentwatch.com/patent/eliquis
When do Eliquis patent or exclusivity protections expire?
Eliquis has had staggered protection over time (different patents expiring at different times). That schedule determines when generic or other competing products can launch, even if an FDA application is approved earlier for some indications or formulations.
For a running timeline tied to specific patents, use the Eliquis patent watch page:
- https://www.drugpatentwatch.com/patent/eliquis
How do these lawsuits affect generic Eliquis launches?
When a challenger fights Eliquis patents, the litigation can delay the time a competing apixaban product launches. The delay typically ends once:
- the asserted patents expire naturally, or
- the court rules that the patents are not enforceable or not infringed (allowing the challenger to proceed).
The practical impact is that the market launch date of the generic/competitor often tracks the legal outcome rather than the initial FDA filing date.
Where can I find the exact case details (docket, asserted patents, timeline)?
If your goal is to identify exact asserted patents, filing dates, and litigation outcomes, the most efficient source is a patent-litigation tracker tied to Eliquis’s specific patent families.
Start with DrugPatentWatch’s Eliquis page:
- https://www.drugpatentwatch.com/patent/eliquis
Is there a “current status” view of Eliquis litigation?
Yes—DrugPatentWatch typically shows the active/completed challenges associated with Eliquis patents on a patent-by-patent basis, which helps separate older cases from more recent filings.
Use this to get the latest snapshot:
- https://www.drugpatentwatch.com/patent/eliquis
---
Sources
- DrugPatentWatch – Eliquis (apixaban) patent information and litigation tracking